PDF
File
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, May 9, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Frontiers in Bioengineering and Biotechnology published an article about the ability of S2 cells to express challenging targets.
Excerpts: "…FAS2FURIOUS is comparable in effort to simple E. coli systems and allows users to clone and test up to 46 constructs in just 2 weeks. Given the ability of S2 cells to express challenging targets, including receptor ectodomains, secreted glycoproteins, and viral antigens, FAS2FURIOUS represents an attractive orthogonal approach for protein expression in eukaryotic cells… …we expect protein expression in S2 to "catch-up" to more common approaches in Sf9 and High Five™ cells, especially for the most challenging targets."
The scientific article is titled "FAS2FURIOUS: Moderate-Throughput Secreted Expression of Difficult Recombinant Proteins in Drosophila S2 Cells". Paper reference: Coker et al., Front. Bioeng. Biotechnol. (2022) https://doi.org/10.3389/fbioe.2022.871933. The article can also be found via this link (https://www.frontiersin.org/articles/10.3389/fbioe.2022.871933/full), as well as via the Research Publications (https://expres2ionbio.com/newspublications/research-publications/) page of ExpreS[2]ion's website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se